Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211365 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1MRGPRX4CYP2A6POLB | |
| SCHEMBL3815862 | 0.86 | CYP2A6 (0.56) | OPRM1OPRK1MRGPRX4CYP2A6CTNNB1 | |
| SCHEMBL6544511 | 0.84 | PTGS1 (0.47) | OPRM1OPRK1MRGPRX4CYP2A6POLB | |
| SCHEMBL25569794 | 0.83 | OPRM1 (0.46) | OPRM1OPRK1MRGPRX4CYP2A6POLB | |
| SCHEMBL12855291 | 0.79 | MAPT (0.48) | OPRM1OPRK1MRGPRX4POLBKDM4E | |
| SCHEMBL25569764 | 0.77 | OPRM1 (0.53) | OPRM1OPRK1MRGPRX4MAPK8MAPK10 | |
| SCHEMBL3150204 | 0.76 | CYP2A6 (0.46) | OPRM1OPRK1MRGPRX4CYP2A6PTGS1 | |
| SCHEMBL154793 | 0.76 | CYP2A6 (0.47) | OPRM1OPRK1MRGPRX4CYP2A6AKR1C3 | |
| SCHEMBL5580227 | 0.74 | SLC7A5 (0.54) | PTGS1KDM4E | |
| SCHEMBL27718663 | 0.73 | POLB (0.36) | POLBPTGS1AKR1C3AKR1C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| US-11896577-B2 | Short-acting psychoactive compounds of the MDMA class | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-116096715-A | Beneficial benzothiophene compositions for mental disorders or enhancement | 泰科根公司 | 2023-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | OPRM1 22/4885OPRK1 47/4885MRGPRX4 848/4885 |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | OPRM1 1733/4885OPRK1 1113/4885MRGPRX4 980/4885 |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | OPRM1 22/4885OPRK1 47/4885MRGPRX4 848/4885 |
| US-11896577-B2 | Short-acting psychoactive compounds of the MDMA class | PNMT, HTR2C, SLC18A2 | OPRM1 21/4885OPRK1 51/4885MRGPRX4 1312/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | OPRM1 8/4885OPRK1 37/4885MRGPRX4 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.